The DFCI approach – Dr Lewis Silverman
Objectives : 1. To recognize the treatment evolution of acute lymphoblastic leukemia from the Dana-Farber Cancer Institute Consortium 2. To recognize the importance of asparaginase in the treatment of ALL
9:00 AM
9:30 AM
The BFM approach – Dr Gunnar Cario
Objectives : 1. To understand the role of multicenter randomized clinical trials for success in treatment of ALL in children 2. To understand the limits of treatment intensification and the chance of immunotherapy for further improvement of therapy
10:00 AM
The COG approach – Dr Mignon Loh
Objectives : 1. To recognize the treatment evolution of acute lymphoblastic leukemia from the Children’s Oncology Group 2. Reconnaître les facteurs pronostiques qui informent la stratification du risque en LAL pédiatrique (To recognize prognostic factors to inform risk-adapted treatment in pediatric ALL
10:30 AM
The adult approach – Dr Guillaume Richard-Carpentier
Objectives : 1. To distinguish between adult vs. pediatric-inspired regimens in the treatment of adult ALL 2. To determine treatment modifications of pediatric-inspired chemotherapy regimens in the treatment of adult ALL
11:00 AM
Discussion Panel | ALL: From history to legacy – decades of optimization
Objectif : To highlight similarities and differences in the treatment approach among DFCI, COG, BFM and adult protocols
11:30 AM
Lunch
1:00 PM
Genomic landscape of ALL across the age spectrum – Dr Charles Mullighan
Objectives : 1. To describe the genetic basis of response to chemotherapy and immunotherapy in ALL 2. To describe the role of genomic classification in T-ALL an lineage ambiguous leukemia.
1:30 PM
Genomics in pediatric oncology : the Quebec experience* – Drs Sonia Cellot & Vincent‑Philippe Lavallée
Objectives: 1. To understand the clinical applications of whole-transcriptome sequencing in the molecular classification of acute lymphoblastic leukemia 2. To understand the clinical applications of long-read DNA sequencing in the molecular classification of acute lymphoblastic leukemia
2:00 PM
Discussion Panel | ALL - Genomic discoveries and novel technologies
Objectif : To describe the spectrum of technologies used in the molecular classification and risk stratification of patients with ALL
2:30 PM
Coffee break
3:00 PM
De-escalation of therapy in childhood and infant ALL – UK approach – Dr Jack Bartram
Objectives : 1. Overview of the UK (CCLG - Children's Cancer and Leukaemia Group) approach for treatment of acute lymphoblastic leukaemia 2. De-escalation of cytotoxic chemotherapy, using blinatumomab in standard of care guideline and the collection of real word data.
3:30 PM
Immunotherapy in adult ALL – Dr Julie Bergeron
Objectives : 1. Review how frontline use of blinatumomab and the overall use of inotuzumab fit into the treatment approach. 2. Share perspectives on the role of CAR‑T therapy in patient care pathways.
4:00 PM
Precision medicine approaches in pediatric Ph+ and Ph-like ALL – Dr Thai Hoa Tran
Objectives : 1. To recognize the clinical features and outcomes of children of Ph+ and ABL-class Ph-like ALL. 2. To describe treatment strategies in the management of Ph+ and ABL-class Ph-like ALL in children.
4:30 PM
Discussion Panel : ALL – A new era of therapies
Objectif : To understand the role of immunotherapy in the frontline treatment protocols for pediatric and adult ALL
